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Tissue-specific amino acid transporter partners ACE2 and
collectrin differentially interact with hartnup mutations
Abstract
BACKGROUND & AIMS: Hartnup amino acid transporter B(0)AT1 (SLC6A19) is the major luminal
sodium-dependent neutral amino acid transporter of small intestine and kidney proximal tubule. The
expression of B(0)AT1 in kidney was recently shown to depend on its association with collectrin
(Tmem27), a protein homologous to the membrane-anchoring domain of angiotensin-converting
enzyme (ACE) 2. METHODS: Because collectrin is almost absent from small intestine, we tested the
hypothesis that it is ACE2 that interacts with B(0)AT1 in enterocytes. Furthermore, because B(0)AT1
expression depends on an associated protein, we tested the hypothesis that Hartnup-causing B(0)AT1
mutations differentially impact on B(0)AT1 interaction with intestinal and kidney accessory proteins.
RESULTS: Immunofluorescence, coimmunoprecipitation, and functional experiments using wild-type
and ace2-null mice showed that expression of B(0)AT1 in small intestine critically depends on ACE2.
Coexpressing new and previously identified Hartnup disorder-causing missense mutations of B(0)AT1
with either collectrin or ACE2 in Xenopus laevis oocytes showed that the high-frequency D173N and
the newly identified P265L mutant B(0)AT1 transporters can still be activated by ACE2 but not
collectrin coexpression. In contrast, the human A69T and R240Q B(0)AT1 mutants cannot be activated
by either of the associated proteins, although they function as wild-type B(0)AT1 when expressed alone.
CONCLUSIONS: We thus show that ACE2 is necessary for the expression of the Hartnup transporter in
intestine and suggest that the differential functional association of mutant B(0)AT1 transporters with
ACE2 and collectrin in intestine and kidney, respectively, participates in the phenotypic heterogeneity
of human Hartnup disorder.
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Abbreviation List 
 
AB, antibody 
ACE2, angiotensin-converting enzyme 2 
ace2 -/-, ace2 female null mouse  
ace2 -/y, ace2 male null mouse 
ace2 +/+, ace2 female wild type mouse 
ace2 +/y, ace2 male wild type mouse 
AP substrate, alkaline phosphatase substrate  
B0AT1, Broad range neutral amino acid transporter 1  
BBMV, brush border membrane vesicles 
coll -/y, collectrin male null mouse 
coll +/y, collectrin male wild type mouse 
C-term, Carboxyl-terminal 
HRP substrate, horseradish peroxidase substrate 
KO, knock-out mouse 
MES, 2-(N-morpholino)-ethanesulfonic acid 
MTSEA-biotin, 2-(aminoethyl)-methanethiosulfonate-biotin 
NMDG, N-methyl-D-glucamine 
N-term, Amino-Terminal 
PCR, polymerase chain reaction 
PVDF, Polyvinylidenfluorid 
SARS, Severe acute respiratory syndrome 
SARS-CoV,  SARS coronavirus 
SDS, sodium dodecyl sulfate 
SLC6A19, solute carrier family 6, member 19 
SNP, Single nucleotide polymorphism  
TEVC, two electrode voltage clamp 
Vh, holding voltage 
WT, Wild type 
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Abstract 
Background and aims: Hartnup amino acid transporter B0AT1 (SLC6A19) is the major 
luminal sodium-dependent neutral amino acid transporter of small intestine and kidney 
proximal tubule. The expression of B0AT1 in kidney was recently shown to depend on its 
association with Collectrin (Tmem27), a protein homologous to the membrane anchoring 
domain of angiotensin converting enzyme 2 (ACE2). Since Collectrin is almost absent from 
small intestine, we tested the hypothesis that it is ACE2 that interacts with B0AT1 in 
enterocytes. Furthermore, since B0AT1 expression depends on an associated protein, we 
tested the hypothesis that Hartnup-causing B0AT1 mutations differentially impact on B0AT1 
interaction with intestinal and kidney accessory proteins. Results: Immunofluorescence, co-
immunoprecipitation, and functional experiments using wild type and ace2 null mice 
demonstrate that expression of B0AT1 in small intestine critically depends on ACE2. Co-
expressing new and previously identified Hartnup disorder-causing missense mutations of 
B0AT1 with either Collectrin or ACE2 in Xenopus laevis oocytes shows that the high 
frequency D173N and the newly identified P265L mutant B0AT1 transporters can still be 
activated by ACE2 but not Collectrin coexpression. In contrast, the human A69T and R240Q 
B0AT1 mutants cannot be activated by either of the associated proteins although they function 
as wild type B0AT1 when expressed alone. Conclusion: We thus demonstrate that ACE2 is 
necessary for the expression of the Hartnup transporter in intestine and suggest that the 
differential functional association of mutant B0AT1 transporters with ACE2 and Collectrin in 
intestine and kidney, respectively, participates to the phenotypic heterogeneity of human 
Hartnup disorder. 
  
 
Key words: Epithelial transport, enterocyte, amino acid transport, renin-angiotensin system, 
hereditary aminoaciduria, intestinal absorption 
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Introduction 
Hartnup is an autosomal recessive disorder caused by mutations in the SLC6A19 gene that 
encodes the main epithelial neutral amino acid transporter B0AT11, 2. This disorder is 
characterized by neutral aminoaciduria due to impaired amino acid transport in kidney 
proximal tubule epithelial cells whereas the extent of intestinal transport impairment appears 
to be less consistent. Various other clinical symptoms such as pellagra-like rash, cerebellar 
ataxia or other neurological dysfunctions may be present in affected individuals, while other 
subjects remain, besides aminoaciduria, asymptomatic. Phenotypic variability might be 
partially explained by the differential impact of various mutations and the frequent compound 
heterozygosity.  
Differential phenotypic effects of mutations could arise from differential interactions of 
B0AT1 with tissue-specific modulatory and/or associated proteins. We and others have 
previously shown that B0AT1 requires association with Collectrin for luminal surface 
expression in kidney proximal tubule, whereas Collectrin is nearly absent in small intestine, 
the other major site of B0AT1 expression 3, 4. Intriguingly, the closest homolog of Collectrin is 
the angiotensin-converting enzyme 2 (ACE2), which functions as a key carboxypeptidase 
enzyme in the renin angiotensin system. ACE2 is involved in heart and kidney pathologies 5 
and has been identified as the SARS receptor in vitro 6 and in vivo 7. Importantly, previous 
studies have reported ACE2 expression and SARS-CoV replication in human small intestine 8, 
9.  
We first investigated whether ACE2 associates with B0AT1 in mouse small intestine. 
Immunofluorescence, co-immunoprecipitation and functional data presented here clearly 
demonstrate that ACE2 is the specific partner of B0AT1 in small intestine and thus that the 
accessory protein of B0AT1 is tissue specific.  
We then tested the influence of Collectrin and ACE2 on the function of human B0AT1 
Hartnup-causing mutations in the Xenopus laevis oocyte expression system. Our results 
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suggest that specific defects in interaction with tissue specific accessory proteins may lead to 
differential defects in intestinal versus kidney (re)absorption of neutral amino acids and 
thereby participate to the variability of phenotypes observed in Hartnup subjects. 
 
Methods 
Animals 
The ace2 and collectrin wild-type (WT) and knock-out (KO) mice were housed in standard 
conditions and fed a standard diet. Generation of the KO mice was described elsewhere 3, 5. 
Animals were either anaesthetised and perfused with a fixative solution for localization 
studies or euthanized to remove small intestine and kidneys. Scraped small intestine mucosa 
cells and total kidneys were frozen in liquid nitrogen for subsequent RNA extraction or brush 
border membrane vesicles (BBMV) preparation. All procedures for mice handling were 
according to the Swiss Animal Welfare laws and approved by the Kantonales Veterinäramt 
Zürich. 
Organ fixation 
Male mice were anesthetized with ketamine and xylazine (90 mg/kg body weight, Narketan 
10, Vétoquinol, Lure, France) and Xylazine (10 mg/kg body weight, Xylazin, Streuli, Uznach, 
Switzerland) intraperitoneally and perfused through the left cardiac ventricle with phosphate-
buffered saline (PBS, phosphate buffer, pH 7.4) followed by a buffered paraformaldehyde 
solution (4%, pH 7), as previously described 10. Small intestine was then harvested, incubated 
overnight in paraformaldehyde solution, washed several times with PBS and stored in PBS-
0.02% sodium azide at 4°C. Tissues were then mounted with Kryostat OCT (Medite, 
Nunningen, Switzerland), frozen in liquid propane and stored at – 80°C. 
Immunofluorescence  
Immunofluorescence was performed as previously described 11. Primary antibodies were 
diluted (1:200) for rabbit affinity purified anti-mouse B0AT1 11, and (1:100) for affinity 
Camargo et al.,   GASTRO-D-08-00848  6 
purified goat anti-mouse ACE2 (R&D Systems, Minneapolis, USA). Secondary antibodies 
were diluted (1:500) for Alexa Fluor 488 donkey anti-goat IgG and Alexa Fluor 594 donkey 
anti-rabbit IgG (Molecular Probes, Invitrogen, Carlsbad, USA). Digital images were viewed 
by using a Nikon Eclipse TE300 epifluorescence microscope (Nikon Instruments Inc., 
Melville, USA) equipped with a DS-5M Standard CCD camera (Nikon) and acquired with 
NIS-Elements (Nikon). 
Brush Border Membrane preparations  
Brush Border Membrane Vesicles (BBMV) were prepared from small intestine mucosa cells 
and kidneys using the Mg2+ precipitation technique as described elsewhere 12. 
Western blotting  
Western Blotting was performed as previously described 11. Primary antibodies were diluted 
to: 1:1000 goat affinity purified anti-mouse ACE2 (R&D), 1:1000 goat affinity purified anti-
human ACE2 (R&D), 1:2000 or 1:1000 for rabbit affinity purified anti-mouse or anti-human 
B0AT1, respectively 11 (Pineda, Berlin, Germany) and 1:10000 for mouse anti-mouse β-actin 
(Sigma, St Louis, USA). Secondary antibodies were diluted (1:5000) for ECLTM anti-rabbit or 
anti-goat IgG Horseradish Peroxidase linked fragment from donkey or mouse, respectively 
(Amersham Biosciences, Piscataway, USA and  Pierce, Rockford, USA.) or anti-mouse IgG 
Alkaline Phosphatase Conjugate from mouse (Promega, Madison, USA). Antibody binding 
was detected with Immobilon Western Chemiluminescent HRP or AP substrate (Millipore, 
Billerica, USA) and chemiluminescence visualized with a DIANA III camera (Raytest, 
Dietikon, Switzerland). 
Intestinal Ring Uptake 
Uptake of radiolabelled L-isoleucine was performed as previously described 13 on ileum 
segments, with slight modifications. Briefly, everted ileum segments were incubated in 
bubbling (Oxycarbon) Krebs-Tris Buffer (pH 7.4) containing 1mM L-isoleucine (1 μCi 14C-
L-Ile/ml) for 5 min at 37°C. Ileum segments were dried at 55°C O/N on cellulose (Sartorius 
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AG, Goettingen, Germany) and weighed.  Segments were then lysed in 0.75 N NaOH for 6 h, 
neutralised with 10N HCl and the radioactivity was determined by liquid scintillation. Na+ 
was replaced by N-methyl-D-glucamine (NMDG) in the condition without Na+. Amino acid 
transport was expressed relative to dry tissue weight. 
Identification of new Hartnup mutations 
After informed consent  genomic DNA was obtained from whole blood of Hartnup patients as 
previously published 1. Intronic primers to sequence exons and splice sites of each exon were 
chosen. Primer sequences are available on request. PCR products of each exon were separated 
by electrophoresis on agarose gels and specific bands removed for DNA isolation. This DNA 
was sequenced in both directions using a Beckman Coulter CEQ8000 (Beckman Coulter, 
Fullerton, USA) following the manufacturer's protocol. The absence of each recognized 
missense mutation was confirmed in 100 ethnically matched control alleles. 
Isolation and subcloning of cDNAs and site-directed mutagenesis 
Human (h) B0AT1, ACE2 and Collectrin cDNAs were amplified from human kidney 
Marathon-Ready cDNA (Clontech, Mountain View, CA, USA) by PCR using a proofreading 
polymerase (Pfu, Promega, Madison, USA). The primers used are available upon request. The 
amplified ACE2 and Collectrin cDNAs were subcloned in pcDNA3; mouse (m) ACE2 and 
Collectrin in pcDNA 3.1 hygromycin (Invitrogen, Carlsbad, USA). The B0AT1 was sub-
cloned into a pBlueScript modified Xenopus laevis expression vector containing both the 5’ 
and 3’ ends of the β-globin gene (KSM) kindly provided by Dr. Leila Virkki. For expression 
in Xenopus laevis oocytes the plasmids were linearized and used as template for RNA 
synthesis (mMESSAGEmMACHINE™, Ambion, Austin, USA). The mutation in human 
B0AT1 and ACE2 was performed using quick changes site-directed mutagenesis according to 
the manufacturer (Stratagene, La Jolla, USA). The mutation ACE2-R273Q was shown 
previously to be catalytically inactive but normally expressed 14. The B0AT1 mutations were 
done on the SNP V252I, which has been shown to behave like the wild type. 
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Homology model 
The homology model of human B0AT1 transport was based on the crystal structure of 
LeuTAa (NP_214423) as a template using the I-TASSER server 15. The pdb file was 
visualized using Pymol (DeLano Scientific LLC, Palo Alto, USA).   
Transport studies in Xenopus laevis oocytes.  
Expression studies and influx assays using radiolabeled amino acid tracer were performed in 
X. laevis oocytes after 5 to 9 days expression, as described previously 16. Data is expressed in 
pmol / h / oocyte and values obtained for non-injected oocytes are subtracted. 
Electrophysiology using two-microelectrode voltage clamp 
The two-microelectrode voltage clamp (TEVC) technique was used for the recording of 
whole-cell currents from X. laevis oocytes. Recordings were performed at room temperature 
5-9 days after injection with cRNA. Recordings were carried out as previously described 16 at 
a membrane holding potential (Vh) of −50 mV. To control for batch variation in transporter 
expression and measured current, the data from the selectivity experiment were normalized to 
IL-Ile 10mM. Pooled data are shown as mean ± SEM where n represents the number of pooled 
cells. Experimental protocols were repeated at least twice. Nonlinear regression calculations 
were performed using GraphPad Prism™ Version 4.0 (GraphPad Inc., San Diego, USA).  
Labelling of surface proteins in Xenopus oocytes 
Surface labelling of oocytes expressing human B0AT1 alone or co-expressed with mouse 
ACE2 or human Collectrin  was performed using MTSEA-Biotin (Sigma-Aldrich, 
Switzerland) as previously described 17. Samples were separated on a 10% SDS gel and 
immunoblotted with affinity purified rabbit anti- human B0AT1 antibody (Pineda). Signal 
intensity was quantified with the AIDA Image Analyzer (Raytest).  
Immunoprecipitations 
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Mouse brush border membrane proteins: BBMVs were incubated with serum anti-B0AT1 
polyclonal antibody 11 in EBC solution (20 mM Tris-HCl pH 8.0, 120 mM NaCl, 0.5% NP40) 
at 4°C on a rotator. The immunocomplexes were coupled to Immobilized Protein A/G beads 
(Pierce) O/N at 4°C on a rotator. The beads were washed with NET-N solution (20 mM Tris-
HCl pH 8.0, 100 mM NaCl, 0.5% NP40, 1 mM EDTA), and the immunoprecipitate loaded on 
a polyacrylamide gel. Western Blot was performed as described above with anti-mouse 
B0AT1 antibody to check for B0AT1 immunoprecipitation or anti-mouse ACE2 antibody to 
test ACE2 co-immunoprecipitation. To avoid background staining, Protein A/G coupled to 
Alkaline Phosphatase (AP) was used as a secondary antibody (Pierce). 
Xenopus laevis oocytes: Immunopreciptation of human B0AT1, B0AT1 mutants and human 
ACE2 was performed as previously described 18. Briefly oocytes were lysed in EBC buffer (as 
described for BBMV) and the supernatant was first incubated with serum anti-human B0AT1 
and subsequently with Immobilized Protein A/G beads (Pierce) O/N at 4°C on a rotator. 
Western Blot was performed as described above to test for human ACE2 co-
immunoprecipitation. 
Statistics 
Data are presented as means ± standard error of the mean (SEM). Analyses were done by 
running the GraphPad Prism 4.0 software (GraphPad).  Between-group comparisons were 
performed by Student's unpaired t test. Multiple comparisons within groups were performed 
by repeated-measures oneway ANOVA, followed by Tukey post test. Statistical significance 
was accepted at P < 0.05. 
 
Results 
 
ACE2 is the intestinal partner of the amino acid transporter B0AT1 
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We first assessed the potential in vivo role of ACE2 as intestinal B0AT1 associated protein by 
investigating the B0AT1 expression in ace2 null mice 5. Remarkably, B0AT1 protein was 
completely absent in small intestine brush border membranes of mice lacking ACE2 (Figure 
1A, B) whereas it was normally expressed in kidney (Figure 1B). This organ distribution of 
B0AT1 in ace2 null mice mirrors the situation observed in collectrin null mice, where B0AT1 
is absent in kidney and, as shown in this study, normally expressed in small intestine (Figure 
1B). Furthermore, ACE2 was co-immunoprecipitated with B0AT1 from intestinal brush 
border membranes of wild type mice, demonstrating in vivo interaction (Figure 1C).  
The function of B0AT1 was also shown to depend on ACE2 in mouse intestine. We observed 
that the lack of B0AT1 protein expression in the intestine of ace2-/y mice abolished the Na+-
dependant portion of L-isoleucine transport measured in intestinal rings (Figure 1D). The total 
(in the presence of Na+) but not the sodium-independent transport was dramatically reduced 
when compared to the wild type littermates. The equivalent effect was previously shown in 
kidney brush border membrane vesicles of collectrin -/- mice, where the transport was also 
reduced 3.  These data show that ACE2 is essential for expression and function of B0AT1 in 
intestine whereas Collectrin controls B0AT1 expression in the kidney. 
 
ACE2 and Collectrin increase the function of human Hartnup transporter B0AT1 in 
vitro 
The tissue-specific associated proteins Collectrin and ACE2 expressed in Xenopus laevis 
oocytes mimicked their effect in vivo on B0AT1 by stimulating its transport function. 
Expressed alone in oocytes human B0AT1 induced a low amino acid transport rate as shown 
by us and others previously 1, 2. We show here that its co-expression with mouse or human 
ACE2, or human Collectrin increases the transport function ~10-fold (Supplementary Figure 
1A; see supplementary material online at www.gastrojournal.org ). The mouse ortholog of 
Collectrin did not activate human B0AT1, although it has been shown to be effective on 
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mouse B0AT1 3. We have as yet no explanation for this differential impact of the collectrin 
orthologs in the X. laevis expression system. Different from Collectrin, ACE2 has one 
catalytic site. It is a carboxypeptidase, and converts Angiotensin (Ang) I and II to Ang (1-9) 
and (1-7), respectively 19, 20, functionally antagonizing its homolog ACE. We analyze the role 
of the catalytic activity of ACE2 in the functional interaction with B0AT1 (Supplementary 
Figure 1B; see supplementary material online at www.gastrojournal.org). The catalytically 
dead mutant (ACE2 R273Q)14 was as efficient as the wild type in enhancing the B0AT1 
function suggesting that it is not necessary for the interaction. This was expected since human 
Collectrin shares 48% identity with ACE2 at the level of its carboxyl-terminal membrane 
anchor region but entirely lacks the extracellular peptidase domain 21. 
The amino acid selectivity, ion dependence and kinetic characteristics of human B0AT1 co-
expressed with ACE2 are, besides a much higher maximal transport rate, very similar to those 
previously published for human B0AT1 expressed alone 1 (Supplementary Figure 2 A-E; see 
supplementary material online at www.gastrojournal.org). 
 
Differential interaction of accessory proteins with B0AT1 Hartnup mutations  
To address the question whether Hartnup mutations impact on the interaction of B0AT1 with 
its accessory proteins ACE2 and/or Collectrin, we expressed missense mutations alone or 
together with either accessory protein in X. laevis oocytes and analysed their transport 
function and surface expression. Beside five previously described missense mutations and one 
non-synonymous single nucleotide polymorphism (SNP), we characterized four new missense 
mutations identified in patients with neutral aminoaciduria characteristic of Hartnup disorder 
belonging to 4 different families (Table 1), (Supplementary Figure 3A-D; see supplementary 
material online at www.gastrojournal.org) 1, 2. The non-synonymous SNP V252I essentially 
behaved as wild-type B0AT1 when co-expressed with Collectrin and ACE2 (Figure 2A upper 
and middle panels). Interestingly, the observed two to three-fold increase in B0AT1 surface 
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expression measured by surface biotinylation only partially explains the almost ten-fold 
increase in surface transport function induced by co-expression with Collectrin or ACE2 
(Figure 2A lower panel and representative Western blot).   
Surprisingly, Collectrin and ACE2 co-expression differentially impacted on the surface 
expression and function of the two B0AT1 mutants D173N and P265L (Figure 2B). In both 
cases, co-expression with ACE2 increased the transport rate whereas co-expression with 
Collectrin either had the opposite effect or no effect (Figure 2B upper panel). The transport 
function of these mutants was shown to be Na+-dependent as for wild-type B0AT1 (Figure 3 
upper and middle panels). Surface biotinylation experiments suggested that the differential 
function of these B0AT1 mutants with the two associated proteins is due, in the case of 
D173N, to a difference in surface expression, whereas the surface expression appeared in the 
case of P265L to be similar with both associated protein (Figure 2B lower panel and 
representative Western blot). Finally, the mutants D173N and P265L co-precipitated with 
human ACE2, confirming that they interact with ACE2 (Figure 2D).  
We next analyzed the two B0AT1 mutations A69T and R240Q that when expressed alone 
display the same L-isoleucine transport function and ion dependence as wild type B0AT1, 
whereas their transport function was not activated in the presence of either associated protein 
(Figure 2C upper and middle panels and Figure 3 lower panel). In the case of the newly 
described A69T, this was particularly surprising, since its surface expression was increased 
two to three-fold by co-expression with both accessory proteins (Figure 2C lower panel and 
representative Western blot) and its interaction with ACE2 confirmed by co-
immunoprecipitation (Figure 2D). In contrast, the surface expression of R240Q did not appear 
to be increased by the presence of the accessory proteins (Figure 2C lower panel and 
representative Western blot), although the mutant transporter was co-immunoprecipitated 
with human ACE2 to some extent (Figure 2D).  
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The mutations R57C, L242P, and E501K have previously been tested by expression in X. 
laevis oocytes, and showed no transport capacity 1, 2. Co-expression of these mutants with 
Collectrin and ACE2 did not change their impaired function and did not affect their cell 
surface expression (Figure 4). Similarly, the newly described mutations G93R and P579L lack 
function also in the presence of associated proteins. However, the surface expression of G93R 
was selectively increased by ACE2 (Figure 4 lower panel and representative Western blot).  
 
Discussion 
Recently we have reported that Collectrin (Tmem27) associates with and controls the 
expression of B0AT1 in kidney proximal tubule 3, 4. In this study, we demonstrated a novel 
and unexpected function of the important renin-angiotensin system enzyme ACE2 that 
associates with the luminal amino acid transporter B0AT1 in small intestine and thereby 
controls its surface expression and function.  B0AT1 associates in a tissue specific manner 
with ACE2 in small intestine and with Collectrin in the kidney. Thus, ace2 and collectrin null 
mice can be used to study the role of the neutral amino acid transporter B0AT1 in kidney and 
intestine independently.  
The same effect was observed on human B0AT1 ortholog expressed in the heterologous 
expression systems, Xenopus laevis oocytes. The co-expression of the two accessory proteins, 
ACE2 or Collectrin, increased the transport rate and the cell surface expression of the 
transporter. The analysis of the function and surface expression of B0AT1-Hartnup causing 
mutations expressed alone or together with the two partner proteins allowed us to discriminate 
classes of mutants that might differentially impact on the phenotype of the patients.  
The Hartnup-causing mutations in B0AT1 are localized throughout the protein, as shown on 
the homology model depicted in Figure 5. This is also the case for the largest class of 
mutations mentioned here, the “dead” mutants, three of which were published earlier (R57C, 
L242P, E501K1, 2) and two of which are newly described here (G93R and P579L) 
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(Supplementary Figure 3 C and D; see supplementary material online at 
www.gastrojournal.org). These mutants do not display any measurable function which is 
consistent with the fact that, with one exception, they do not reach the plasma membrane, 
neither when expressed alone, nor upon co-expression with associated proteins. 
The second class of mutants corresponds to those which expressed alone function as wild type 
B0AT1 but are not stimulated by either associated protein. In the case R240Q, its surface 
expression is not increased upon co-expression with ACE2 or Collectrin, but co-
immunoprecipitation demonstrates that its interaction with ACE2 is not abolished. Assuming 
a qualitative effect of the R240Q mutation on this interaction, our observation is nonetheless 
potentially compatible with the hypothesis recently put forward by the group of Broer, namely 
that the localization of this mutation at the surface of B0AT1 might impact on the interaction 
with accessory proteins 22. Further studies are necessary to clarify the mechanism by which 
this mutation, initially classified as a SNP, prevents the normal activation of B0AT1 by the 
accessory proteins. In contrast, in the case of the other functional mutant of this class A69T, 
an increase in cell surface expression of this mutant B0AT1 was demonstrated upon 
interaction with the associated proteins (Figure 2C and D). One possible explanation of why 
the increase in surface-expression did not lead to an increase in transport rate is that 
ACE2/A69T-B0AT1 heterodimers reaching the cell surface remain inactive, meaning that the 
associated protein inhibits the function of A69T-B0AT1. The fact that the residue mutated in 
A69T is part of a highly conserved motif (NGGGAF) shown to undergo conformational 
changes during the transport cycle is compatible with this hypothesis 23. Additionally, that the 
co-expression of ACE2 or Collectrin apparently activates the transport rate of wild type 
B0AT1 several-fold more than it increases its surface expression (~10-fold versus ~2.5-fold) 
also suggests that associated proteins may impact on transporter function, though normally by 
increasing the cycling rate.  
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The most intriguing class of mutants in regards to its potential phenotypic impact is 
represented by D173N and the newly described P265L. These mutants differentially interact 
with the two tissue-specific accessory proteins such that their function is stimulated only by 
the intestine-specific associated protein ACE2. Interestingly, the D173N allele is relatively 
frequent in unrelated Hartnup pedigrees and can also be observed in healthy Caucasians with 
a high heterozygote frequency (1:122 healthy individuals) 2, 24. We know of no potential 
selective advantage for heterozygous carriers that explains the persistence and geographic 
spread of this mutant allele 25, 26. The selective functional interaction of D173N with the 
intestinal accessory protein ACE2 might prevent deleterious effects due to a lack of amino 
acid absorption and thereby allowing the “survival” of this frequent allele. Although as yet no 
evidence of genotype-phenotype relationship performed in patients were reported, studies 
performed long before the identification of the Hartnup transporter have shown that intestinal 
amino acid absorption differs between Hartnup subjects 27, 28. 
Taken together, our data demonstrate that the expression and function of the main epithelial 
amino acid transporter is modulated by tissue-specific accessory proteins. Moreover, the 
intriguing fact that these accessory proteins can interact differentially with Hartnup mutations 
and thereby differentially affect kidney and intestinal amino acid transport function suggests 
that Collectrin and ACE2 may also contribute significantly to the phenotypic heterogeneity 
among individuals with Hartnup disorder. 
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Table 1: Missense mutations in the SLC6A19/human B0AT1 gene described in subjects 
with Hartnup disorder. 
 
Protein wt mutation Position from the atg Position in the protein 
R57C1 Cgc Tgc 169 1st TMS 
*A69T Gcc Acc 205 2nd TMS 
*G93R Ggg Agg 277 2nd TMS 
D173N2 Gac Aac 517 2nd EL 
R240Q2 cGa cAa 719 3th EL 
L242P2 cTg cCg 725 3th EL 
*P265L cCg cTg 794 6th TMS 
E501K2 Gag Aag 1501 10th TMS 
*P579L Ccg Tcg 1735 6th EL 
New mutations (*) identified in this study. The previously published mutations by 
Kleta et al. 1 and Seow et al. 2 are also listed. R240Q was initially described as SNP 
by Seow et al2. TMS = transmembrane segment, EL = extracellular loop. 
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Figure 1.  ACE2 and B0AT1 co-localization and functional interaction. 
(A) Immunofluorescence analysis shows that B0AT1 protein expression is lost in small 
intestine of ace2 null mice. Small intestine sections from ace2+/y and ace2-/y were co-labelled 
with antibodies against ACE2 (green) and B0AT1 (red), and additionally viewed by phase 
contrast (PC). (B) Western blot analysis shows that B0AT1 is absent in small intestine but 
present in kidney brush border membranes of ace2 null mice, whereas B0AT1 is expressed in 
small intestine and absent from kidney brush border membranes in coll null mice. The loading 
of brush border membranes (2.5-20 μg) was tested using a β-actin antibody (βA). Note that 
male ace2+/y or ace2-/y and female ace2+/+ or ace2-/- mice were used with similar results.  (C) 
Co-immunoprecipitation shows interaction of ACE2 with B0AT1 in mouse small intestine. 
Complexes were immunoprecipitated (IP) from small intestine brush border membrane 
vesicles (BBMVs) using anti-B0AT1 antibody (AB) and analysed by Western Blot (WB) 
using anti-mouse ACE2 antibody. (D) Na+-dependant uptake of L-isoleucine (L-Ile) is 
abolished in ileum segments from ace2-/y mice. The transport was measured in the presence 
(empty bar) and in the absence (solid bar) of sodium. Data points represent means values of 4 
intestinal ring uptakes from independent experiments ± SEM, ***p<0.001, ns = not 
significant.  
Figure 2.  Differential function of Hartnup mutations co-expressed with Collectrin or 
ACE2 in X. laevis oocytes. Wild type and mutant human B0AT1 are shown in this figure as 
three groups with different functional characteristics and labelled A-C.  (A) The transport 
function and the surface expression of both wild type and non synonymous SNP V252I of 
B0AT1 are increased by co-expression with human Collectrin or  mouse ACE2.  (B) The 
relatively low transport activity of B0AT1 D173N and P265L mutants expressed alone is 
increased by co-expression with ACE2 but not with Collectrin. The surface expression of the 
D173N mutant is also significantly increased by co-expression with ACE2.  (C) The wild 
type-like function of the A69T or R240Q mutants expressed alone is not increased in the 
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presence of Collectrin or ACE2 although; in the case of A69T its surface expression is 
increased. The upper panels of A-C show the transport function measured as radiolabelled L-
isoleucine (L-Ile) uptake (means ± SEM of 13-31 oocytes from 3 independent experiments) 
and the middle panel the transport function as current measured by TEVC (9-11 oocytes from 
3 batches). *P<0.05, ***P<0.001. The lower panels show the surface expression assayed by 
Western blot using surface-biotinylated proteins and a representative Western blot. The data 
correspond to the means ± SEM (n = 3-5 independent experiments) of the results normalized 
to the value obtained for B0AT1 expressed alone. For the transport experiments the 
significance was evaluated using ANOVA with Tuckey post-test and for the surface 
biotinylation the comparison of means was done by unpaired t test.  (D) B0AT1 and the 
mutants D173N, P265L, R240Q and A69T interact with ACE2 in X. laevis oocytes. The 
transporters expressed alone or together with human ACE2 were immunoprecipitated (IP) 
from oocyte lysates using anti-human B0AT1 antibody and complexes were analysed by 
Western Blot (WB) using anti-human ACE2 antibody. NI = non-injected.  
 
Figure 3. The ion dependency of D173N, P265L, A69T and R240Q co-expressed with 
ACE2 or Collectrin is not altered: Transport is Na+- but not Cl--dependent. Wild type 
human B0AT1 (WT), and the mutants D173N, P265L, A69T and R240Q were expressed 
alone or with human Collectrin or mouse ACE2. The ion dependence was tested by 
substituting Na+ with NMDG (n-methyl-D-glucamine) and substituting Cl- with gluconate. 
Function was assayed by influx of radiolabeled L-isoleucine (L-Ile). For each mutation, three 
independent experiments (15-24 oocytes) were pooled. Comparison of means was done by 
analysis of the variances (ANOVA) with Tuckey as post test. Data represent means ± SEM. * 
p<0.05, **p<0.01, ***p<0.001. ns, not significant.  
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Figure 4. The B0AT1 mutants R57C, G93R, L242P, E501K and P579L exhibit no 
transport activity when expressed alone or co-expressed with Collectrin or ACE2. 
Function was assayed by influx of radiolabeled L-isoleucine (L-Ile) (upper panels) or TEVC 
(middle panels). For each mutant three independent experiments (13-31 oocytes for influx and 
9-11 for TEVC) were pooled. Comparison of means was done by analysis of the variances 
(ANOVA) with Tuckey as post test. Data represent means ± SEM. ns, not significant. Cell 
surface expression of labelled proteins (lower panels) was analysed by Western blot. The 
bands were quantified and data normalized to the values obtained from oocytes expressing 
B0AT1 proteins alone. For each mutation three to four independent experiments were pooled. 
Comparison of means was done by unpaired t test. Data represent means ± SEM. * p<0.05. 
ns, not significant.  
 
 Figure 5.  Missense mutations in the SLC6A19 gene causing Hartnup disorder. The 
model of B0AT1 is based on the Slc6 bacterial homologue from Aquifex aeolicus LeuTAa 29 
and the transmembrane segments are numbered. The localization of mutations causing a loss 
of surface expression (R57, G93, L242, E501, P579) are depicted in the left panel. The sites 
of mutations leading to a differential interaction with the two accessory proteins (D173 and 
P265) are depicted as black spheres on the middle panel, and the sites of the mutations 
preventing both accessory proteins of stimulating the transport function are depicted on the 
right panel (A69 and R240). 
 
 
Appendix 
Supplementary data 
Supplementary data associated with this article can be found in the online version. 
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